PREMPRO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PREMPRO (PREMPRO).
PREMPRO is a combination of conjugated estrogens and medroxyprogesterone acetate. Estrogens bind to estrogen receptors, activating gene transcription and exerting effects on various tissues. Medroxyprogesterone acetate is a progestin that suppresses endometrial proliferation, reducing the risk of endometrial hyperplasia associated with unopposed estrogen therapy.
| Metabolism | Conjugated estrogens are metabolized primarily in the liver via CYP3A4. Medroxyprogesterone acetate is metabolized in the liver via hydroxylation and conjugation, primarily by CYP3A4. |
| Excretion | Conjugated estrogens are primarily excreted in urine (renal elimination accounts for ~50-80% of total clearance) as glucuronide and sulfate conjugates. A smaller fraction undergoes biliary excretion (~10-20%) and is eliminated in feces via enterohepatic circulation. |
| Half-life | The terminal elimination half-life of conjugated estrogens (primarily estrone and equilin) ranges from 10-24 hours (mean ~15 hours) after oral administration. This supports once-daily dosing with steady-state achieved within 5-7 days. |
| Protein binding | ~98% bound to serum albumin and sex hormone-binding globulin (SHBG). Binding is non-saturable at therapeutic concentrations. |
| Volume of Distribution | Apparent volume of distribution (Vd) for estrone is approximately 0.5-1.0 L/kg, indicating distribution into total body water and some tissue binding. Clinical significance: reflects moderate peripheral tissue uptake. |
| Bioavailability | Oral bioavailability of conjugated estrogens is approximately 40-60% due to first-pass hepatic metabolism (glucuronidation and sulfation). Coadministration with food does not significantly alter absorption. |
| Onset of Action | Onset of clinical effects (e.g., relief of vasomotor symptoms) is typically observed within 2-4 weeks of daily oral administration. Partial symptom relief may occur as early as 1 week. |
| Duration of Action | The pharmacodynamic duration (e.g., suppression of hot flashes) lasts approximately 24 hours after a single oral dose, consistent with once-daily dosing. Sustained endometrial protection requires continuous daily administration. |
One tablet orally once daily; each tablet contains conjugated estrogens 0.625 mg and medroxyprogesterone acetate 2.5 mg or 5 mg.
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment provided; use caution in patients with renal impairment. |
| Liver impairment | Contraindicated in patients with hepatic impairment or active liver disease; no dose adjustment recommendations for mild impairment. |
| Pediatric use | Not indicated for use in pediatric patients. |
| Geriatric use | Use the lowest effective dose for the shortest duration; consider alternative therapies due to increased risk of cardiovascular events, dementia, and breast cancer in women over 65. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PREMPRO (PREMPRO).
| Breastfeeding | PREMpro is excreted in human milk. M/P ratio is not specifically reported for conjugated estrogens/medroxyprogesterone; estrogens concentrate in milk with an M/P ratio of approximately 0.2-0.5 for estradiol/progesterone. Use during lactation is not recommended; may reduce milk quantity and quality. |
| Teratogenic Risk | PREMpro is contraindicated in pregnancy. First trimester: Exposure may cause congenital malformations, including cardiovascular and CNS defects, similar to other sex hormones. Second and third trimesters: Associated with genitourinary tract anomalies and feminization of male fetuses (hypospadias). Risk is highest with prolonged use. |
■ FDA Black Box Warning
Estrogens should not be used to prevent cardiovascular disease. The Women's Health Initiative (WHI) substudy reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50-79 years of age) during 5 years of treatment with daily oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg), relative to placebo.
| Serious Effects |
["Known or suspected pregnancy","Undiagnosed abnormal genital bleeding","Known or suspected breast cancer (except in appropriately selected patients)","Known or suspected estrogen-dependent neoplasia","Active or past history of venous thromboembolism (e.g., DVT, PE)","Active or past history of arterial thromboembolism (e.g., stroke, MI)","Known protein C, protein S, or antithrombin deficiency or other thrombophilic disorders","Hypersensitivity to any component of the product","Known liver impairment or disease","Known or suspected pregnancy"]
| Precautions | ["Increased risk of cardiovascular events (MI, stroke, VTE)","Increased risk of breast cancer, especially with combined estrogen-progestin therapy","Endometrial cancer risk with unopposed estrogen; use with progestin reduces but does not eliminate risk","Dementia risk (increase in women >65 years)","Gallbladder disease","Hypercalcemia in patients with breast cancer and bone metastases","Fluid retention, hypertension, hypertriglyceridemia","Angioedema, hereditary or acquired","Exacerbation of endometriosis, hepatic hemangiomas, porphyria, and systemic lupus erythematosus"] |
Loading safety data…
| Fetal Monitoring | Monitor for signs of thromboembolism, hypertension, and fluid retention in the mother. Fetal monitoring includes ultrasound for growth restriction and anomalies if inadvertent exposure occurs. |
| Fertility Effects | Estrogen-progestin combinations suppress ovulation and interfere with implantation, reducing fertility. Reversible upon discontinuation. |